![](https://news.europawire.eu/wp-content/uploads/2013/10/gsk.jpg)
LONDON, 9-10-2014 — /EuropaWire/ — Stiefel, a GSK company, today announced the start of a phase III study to evaluate the efficacy and safety of subcutaneous ofatumumab in patients with pemphigus vulgaris, a rare autoimmune skin disorder. The global study … Read the full press release